SciELO - Scientific Electronic Library Online

 
vol.44 issue2Consensus to identify the dangerous drugs risks in hospital pharmacy servicesDisease modifying therapies in multiple sclerosis: cost-effectiveness systematic review author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Farmacia Hospitalaria

On-line version ISSN 2171-8695Print version ISSN 1130-6343

Abstract

CALVO-ARBELOA, María; INSAUSTL-SERRANO, Ana María; ARRONDO-VELASCO, Amaya  and  SAROBE-CARRICAS, María Teresa. Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease. Farm Hosp. [online]. 2020, vol.44, n.2, pp.62-67.  Epub Sep 28, 2020. ISSN 2171-8695.  https://dx.doi.org/10.7399/fh.11325.

Objective:

Inflammatory bowel disease comprises a group of chronic relapsing inflammatory disorders affecting the bowel. In the last decade, the advent of biological drugs brought about a drastic change in the treatment of the disease. Adalimumab, golimumab and ustekinumab are three biologic agents that patients can self-administer subcutaneously after collecting them from the pharmacy department. However, for the treatment to be effective, adherence is paramount. The purpose of the present study is to evaluate adherence in patients who collected all three drugs from the dispensary of a tertiary care hospital.

Method:

A cross-sectional observational analysis was carried out of patients who had been receiving treatment with adalimumab, golimumab and ustekinumab for at least four months. The medication possession ratio was calculated based on information extracted from the pharmacy dispensing records. Patients with a ratio < 85% were enrolled in the study and asked to respond to Morisky-Green Medication Adherence Questionnaire.

Results:

One-hundred and seventy-eight patients were included, of whom 60.1% (107) were male and 30.9% (55) had been treated pre viously with other biologics. According to the pharmacy dispensing re cords, mean adherence was 91.79%, with 45 patients (25.28%) classified as scarcely compliant (< 85%). The Morisky-Green Medication Adherence Questionnaire revealed that carelessness about administering the drug at the right time and forgetfulness were the main reasons for therapeutic non-adherence. Female sex (odds ratio 0.42; p = 0.013) and lengthy treatments (p = 0.002) were associated to lower adherence rates.

Conclusions:

Although most patients in the studied population were seen to be compliant, low levels of adherence were observed in a number of patients who would benefit from interventions aimed at boosting their adherence. It must be said, however, that the statistical power of this study should be enhanced in order to increase the significance of the results obtained.

Keywords : Therapeutic adherence; Biological therapy; Adalimumab; Golimumab; Ustekinumab; Inflammatory bowel disease.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )